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PHYTOTHERAPY AND THE NEW PARADIGM OF DRUGS MODE OF ACTION. 
 
RESUMEN 
La farmacología ha sido refractaria a las contribuciones del etnofarmacología en 
términos de paradigmas para el uso de las drogas o el modo de acción. Los 
patrones complejos encontrados a menudo en evaluaciones de los extractos de 
plantas medicinales, sugieren que los efectos de las drogas vegetales se pueden 
fundamentar a menudo en bases farmacodinámicas más complejas que las 
relaciones droga/ efecto más usuales. Las características farmacológicas de las 
hierbas pueden resultar de varios ingredientes activos, de las interacciones entre 
éstos, o de ingredientes que poseen múltiples mecanismos de acción. Este 
artículo se centra en la psicofarmacología de las hierbas a la luz de nuevos 
paradigmas de la acción drogas psicotrópicas. Se sugiere que la comprensión de 
conceptos y de prácticas médicos tradicionales puede conducir al desarrollo 
innovador de las drogas.  
 




Pharmacology has been refractory to the contributions of ethnopharmacology in 
terms of paradigms for drugs use or mode of action. The complex patterns often 
found in evaluations of medicinal plant extracts suggest that the effects of plant 
drugs may often be based on a more complex pharmacodynamic basis than the 
more usual drug/effect relationships. Pharmacological properties of herbals may 
result from various active ingredients, interactions among those, or ingredients 
possessing multiple mechanisms of action. This paper focuses on the 
psychopharmacology of herbals in the light of newer paradigms of psychotropic 
drug action. It is suggested that understanding of traditional medical concepts 
and practices can lead to innovative drug development. 
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Traditional (indigenous) and modern (western 
biomedical) medical systems evolved from diverse 
definitions of reality, are related to different  and 
cosmovisions, and are therefore based on different 
paradigms. In spite of these gaps peoples worldwide 
establish dialogues and make use of different systems to 
maintain or re-establish health (1-4). Interestingly, most 
traditional systems share the practice of utilizing raw 
material from nature processed into drugs or food, or 
more recently food supplements, for therapeutic 
purposes. 
    
Within the context of drug development, interest in 
traditional medical systems is mostly focused on the use 
of plants processed as traditional medicines. The 
underlying understanding is that at least some of the plant 
species that constitute the basis of such preparations may 
contain therapeutically useful compounds, to be further 
developed into western type drugs (5). Nonetheless, the 
fact that traditional medical systems are organized as 
cultural systems (6-7), allows for profound differences in 
meanings of health, disease, and disease etiologies (8-9). 
Accordingly, such differences result in a variety of 
therapeutic practices not easily accommodated in the bio- 
mechanical paradigm of modern medicine. 
 
The purpose of this paper is to review some prevailing 
features of traditional medicines in the context of the 
current understanding of mechanisms of action of 
psychoactive drugs. Comparisons of folk and 
contemporary healing concepts have been thoroughly 
explored by social scientists and medical anthropologists, 
in the light of ethnomedicine and of ethnopharmacology 
(9), and are beyond the purpose of this paper. The scope 
of this discussion is limited to some of the features of 
traditional medicines that are of relevance for 
understanding the way traditional medical practices, 
including plant medicines, affect brain functions. 
Concepts such as diet, prevention, low dose/long term 
posologies, and complex mixtures, often central to 











Within the classical humoral systems (prevailing in 
Asiancountries and several Central and South American 
ethnic groups), good health is perceived as a balance 
between physical elements and the body humors (10). 
Foods and disease conditions are assigned temperature 
and moisture qualities or attributes; accordingly, hot 
illnesses are treated by consuming cold foods, and a wet 
disease is treated by dry foods. 
 
In line with the western-like context of drug/body 
interaction, there is the commonly found concept of 
foods as containing substances that interact with body 
functions. Observing a special diet, preventing or 
increasing consumption of certain food-medicines, is 
frequently requested or recommended in association with 
other therapeutic measures in various societies (11).  
 
In the context of CNS, persisting deficits in nutrition can 
lead to neurologic diseases; conversely, in several 
genetically determined neurologic diseases, treatments 
include either elimination of certain foods or 
supplementation with specific vitamins (12). It has been 
shown that alterations in tryptophan consumption 
significantly alters mood and behavior in selected groups 
of individuals (13), and that phenolic antioxidants, such 
as those found in wine, have a protective effect against 
atherosclerosis (14). 
 
The increasing attention and comprehensive analysis of 
data relevant to the effects of ingestion of chemicals from 
plants in the maintenance/improvement of body functions 
and/or disease prevention (15-17) may reveal data to 
further substantiate specific interactions between dietary 
restrictions (or impositions) and functionality of given 
organs or tissues. Perhaps the growing market and quick 
acceptance of nutraceuticals may be associated to a return 
to earlier forms of behavior, when various societies did 
not make evident distinctions between food and medicine 
(11).  
 
3.  PREVENTION 
 
The concept of well-being varies among peoples. Besides 
the ingestion of curative or preventive foods, some types 
of remedies are used chronically  “because it is good for 
health”, to prevent the appearance of certain diseases, 
and/or easy to slow the process of aging. For the 
Matsigenka Indians (Perú), well-being embraces physical 
and psychological health, successful gardening and 
hunting, and harmonious social interaction. Accordingly, 
Matsigenka medicine includes treatments for various 
culture-specific emotional and psychological syndromes, 
with plant species that apparently may be psychoactive 
(18).  
 
In Latin America the use of “tonics” or “nerve tonics” are 
widespread, especially by the elders, by patients 
recovering from CNS illnesses, and as a “general 
stimulant” to cope with high physical or psychological 
stress situations. The pharmacological meaning of such 
tonics has yet to be elucidated (19).  
 
In this context, it is illustrative to the rekindled interest in 
adaptogens, a term coined in 1947 by the Russian 
scientist Lazarev, designating agents which allow 
organisms to counteract stressors, helping the organism 
to be “adapted” to intense demands (20-21). Relevant to 
this discussion is that the mode(s) of action of adaptogens 
have been associated with a variety of cellular and 
molecular mechanisms, including increased synthesis of 
proteins or nucleic acids, increased formation of glucose-
6-phosphate, catecolaminergic synaptic modulation, 
antioxidant activity, immunostimulation, the 
prostaglandins, or even genetic expression  (22).  
 
We suggest that thorough scientific studies of non-
western category of drug action may reveal not only new 
prototypic drugs, but extremely useful new drugs and 
strategies to beneficially interfere with, minimize or 
prevent multifactorial illnesses and age associated 
decline. 
 
4. LOW DOSE, LONG TERM  
 
As in western medication, posology (dose and regimen) 
is usually well defined by medicinal plant specialists 
(23). Traditional formulations of medicinal plants 
processed for therapeutic purposes (such as teas, syrups, 
concoctions, beverages, etc) are expected to be ingested 
over a given period of time, varying with the expected 
length of the condition to be treated, and the time 
required for the remedy to attain its curative goal. Often, 
remedies are recommended for a considerable length of 
time (weeks or months), or even maintained for several 
years; sometimes it is expected that it actually takes 
weeks or months for the efficacy of the treatment (either 
cure or significant amelioration) to become apparent. 
Such long term treatments are usually associated with 
diseases that are chronic and incurable, where the 
treatment aims to keep a given disorder under control 
(such as asthma, epilepsy, diabetes), or minimize diseases 
or processes (such as aging) over the course of several 
years. Considering the yield of active constituents usually 
obtained from the amount of plant material, and mode of 
preparation used to prepare home made remedies (24), it 
is arguable that more often than not, traditional therapies 
involve the repeated ingestion of low doses of active 
substance(s) over a significant period of time.  
 
In pharmacodynamic terms it is expected that this pattern 
of intervention with molecular targets may be profoundly 
different than an acute (single administration) or sub-
chronic (few administrations) challenge to any given 




molecular target. Nevertheless, the traditional posology is 
rarely taken into consideration in evaluating medicinal 
plant extracts or substances in new drug 
screening/development programs. Failure in shaping the 
traditional uses associated with efficacy claims are in part 
related to practical matters: the research design needed to 
match the effects of such repeated interaction with tissues 
and/or molecular targets, requires greater quantities of 
testing materials and poses several other obstacles that 
are difficult to manage. In fact, several in vitro 
methodologies are, unfortunately, inadequate for these 
purposes (25). Nevertheless, the consequences of 
constant and repeated challenges to molecular targets 
have to be taken into consideration at least in interpreting 
results, especially when effects are to be integrated with 
those evaluated through the use of in vivo models.  
 
Specifically referring to the CNS, attention has been 
called to the fact that “it is the adaptive response of the 
nervous system to adequate repeated perturbations 
mediated through these initial targets that produces the 
therapeutic responses” (26). The authors suggest that 
chronic perturbations can lead to different types of 
adaptations (quantitatively and qualitatively), eventually 
resulting in a new functional state. Traditional remedies, 
more often than not, consisting of long term treatments 
with low to moderate doses of active ingredients (as 
those found in traditional preparations) are in line with 
the current paradigm of psychoactive drug action. 
 
5. COMPLEX MIXTURES  
 
In discussing the basis for the effectiveness of Kampö 
medicines, Ishihara (27) calls particular attention to the 
pharmacological antagonism and synergism found among 
the chemical components of the crude extracts that form 
Kampö infusions. Such drug interactions have been 
further substantiated in Kampö formulations (28). 
Complex chemical mixtures have the potential to 
generate interactions, pharmacokinetic benefits, 
pharmacodynamic synergisms or antagonisms, and/or 
combinatorial responses, and the proportion of different 
components in the mixture may determine efficacy and 
safety. Examples have proved that in fact, effects of plant 
based remedies may be due to one active compound with 
a single mechanism of action, to compound(s) that 
possess multiple mechanisms of action (eg.,  Huperzine 
A , to the combined activity of more than one active 
ingredient in a single species (eg., flavonol glycosides, 
phenolic compounds, bilobalide, gingkolides in Gingko 
biloba), or the synergic interactions of different active 
ingredients from several plant species processed as a 
medicinal formula (eg, harmane alkaloids and d-MT-
tryptamine in the ayauhasca drink). 
 
 It has been repeatedly demonstrated that a combination 
of at least 4 substances are responsible for the polyvalent 
pharmacological action and therapeutic properties of the 
Ginkgo biloba extract Egb761, whose beneficial effects 
result from “the combination of its various protective, 
curative and modulating properties against the 
pathological process” (29). In other hand, a single 
alkaloid such as Huperzine A can have a diversity of 
complementary pharmacological properties, such as 
anticholinesterase activity and inhibition of different 
phases of the apoptotic process (30) that are 
complementary in counteracting the diseases processes 
found in Alzheimer disease.  
 
The following are examples of ethnopharmacological 
investigations of medicinal plants with alleged 
psychopharmacological effects are useful to illustrate 
how these issues are of relevance in the context of CNS 
diseases and psychopharmacology.  
 
 
  5.1 Analgesia from Psychotria alkaloids 
In the Brazilian Amazon “Perpétua do Mato”, Psychotria 
colorata (Willd R & S) Muell. Arg, is used to treat 
earache (a handful of cut up fresh flowers in packed in 
banana leaves, and left over warm ashes; the warmed 
flowers are mixed with milk, preferably “mother’s milk”, 
filtered through a piece of cloth and drops are topically 
applied to the ear). Abdominal pain can also be treated 
wit remedies based on this species (roots and fruits are 
mixed with water and left to boil; the decoction is taken 
orally) (31). We reported that alkaloids present in the 
leaves and flowers of P. colorata have marked analgesic 
activity, as evaluated through various pain models (31-
33). Phytochemical analyses of P. colorata flowers 
identified pyrrolidinoindoline alkaloids (Figure 1) as 





Figure1. Hodgkinsine and psychotridine isolated from 
Psychotria colorata (Willd R & S) Muell. Arg. 
 
Pharmacological analyses revealed that hodgkinsine 
produces a dose-dependent naloxone reversible analgesic 
effect in thermal models of nociception, and acts as a potent 
dose-dependent analgesic in the capsaicin-induced pain 
(36); in vivo data complemented by binding studies 
demonstrate that the activation of opioid and blockade of 
glutamate NMDA receptors participate in the hodgkinsine 






























turned out to be associated with the modulation of NMDA 
receptors (37). 
Because some NMDA mediated painful events can be 
difficult to control with opioids alone (e.g., neuropathic pain 
states), it has been argued (38-39) that a combination of 
opioid and NMDA antagonism may be especially 
advantageous in specific clinical conditions. Interestingly 
enough, the combined (opioid and glutamatergic) 
mechanism of action of hodgkinsine alone or the alkaloid 
mixture in the traditional preparation, is in line with current 
strategies for managing severe pain states that respond 
poorly to conventional analgesics. 
 
  5.2 Linalool from Aeollanthus suaveolens 
Other commonly used complex mixtures of compounds 
extensively used in traditional medicines are the essential 
oils. The anticonvulsant profile of linalool is an example. 
 
Because epilepsy is an universal and ancient disease, it is 
reasonable to regard traditional treatments for 
epilepsy/seizures as potential sources of new 
anticonvulsant agents. In fact, dozens of species are 
reported to be used as antiepileptic home remedies, many 
of which have shown activity in preliminary evaluation 
(40). In the search for anticonvulsant plant derived 
compounds, ethnopharmacological surveys were 
conducted within Amazonian traditional communities. A 
widespread recipe that includes Cissus sicyoides 
(Vitaceae), Aeollanthus suaveolens (Lamiaceae), Ruta 
graveolens (Rutaceae) and Sesamun indicum 
(Pedaliaceae) was identified. Following the 
ethnopharmacological methodology, pharmacologically 
monitored chemical investigation lead to the 
identification of linalool as the major active ingredient. 
 
A. suaveolens is one of the best known medicinal species 
in the Amazon, recognized as medicinal by 93% of the 
women interviewed in extractive reserves in the State of 
Acre (41). Because A. suaveolens is heavily aromatic, its 
essential oil was obtained, evaluated and proved active 
(42). The main components identified in the essential oil 
were E-β-farnesen (37.75%), δ-decen-2-lactone (20.6-
44.3%), linalyl acetate (11.32%), linalool (10.49%) and 
δ-decanolactone (0.37-3.02%) (Figure 2).  
 
Figure 2. Main compounds of essential oils from Aeollanthus 
suaveolens 
Although the study of E-β-farnesen is still limited, we 
found that linalyl acetate (43), δ-decen-2-lactone and  δ-
decanolactone (44) were devoid of activity; linalool and  
γ-decanolactone (structurally related to δ-decanolactone) 
proved to be active in several animal models (43-44).  
Moreover, it was found that linalool possesses an 
interesting mechanism of action, modulating the 
glutamatergic and gabaergic neurotransmission (45-46).  
  
Interfering with multiple mechanisms that underlie 
seizures may be necessary to effectively counteract 
epileptic phenomena (47-48). Therefore, the fact the 
anticonvulsant profile of linalool deserves further 
investigation as a potentially novel strategy for 
developing new antiepileptic drugs.  
 
6. CONCLUSIONS AND RECOMMENDATIONS  
Determination, rather than causality, is the current 
extended interpretation of cause-effect relationships in 
physics, “cause” being substituted by “determining 
conditions”, where all the conditions of a process or state 
are equally important.  It has been suggested that some (if 
not all) diseases should be understood as processes, 
where an interplay of multiple factors (genetics, 
environmental exposures, psychic conditions, etc) have to 
be considered (49). In this context it becomes attractive 
to study complex plat extract that eventually can 
modulate more than one target simultaneously.  
Pharmacologists and phytochemists need to be open-
minded and unprejudiced in order to understand 
traditional medical systems as such in order to truly profit 
from studying traditional medical systems rather than 
plant molecules. We suggest that a thorough 
understanding of traditional medical concepts of health 
and disease in general and traditional medical practices in 
particular, can lead to true innovation in paradigms of 
drug action and development. 
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